*May 2024*
Key Takeaways: This combo is a promising treatment for patients with brain mets and/or leptomeningeal disease (LM) after first-line treatment for clinical meaningful rate of time on treatment and radiographic response: Patients with brain mets (PFS=5.9 months; OS=17.9 months) Patients with LM (PFS=8.3 months; OS=14.4 months); RAS/RAF/MAPK pathway mutations and loss of EGFR amplification may contribute to primary and acquired resistance. Future studies are needed in clinical trials for these patients.
